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Background: The study was undertaken to examine the effects of berberine (BBR) on serum homocysteine, lipids
and the aortic lesion in Sprague–Dawley (SD) rats fed with a long-term high-fat diet (HFD).
Methods: Healthy male SD rats weighing 190-210 g received randomly standard diet or a high-fat diet for
24 weeks. After 8 weeks of feeding, rats fed with HFD were randomized to receive berberine (200 mg  kg-1 day-1)
or vehicle by gavage for 16 weeks. After overnight fasting, all rats were sacrificed and total blood samples were also
collected for determinant of fasting serum homocysteine (Hcy), total cholesterol (TC) and low density lipoprotein
cholesterol (LDL-c) levels. The aorta was stained with hematoxylin and eosin (HE) and Sudan Ш to evaluate aortic
lesion. The livers were dissected out and snap-frozen in liquid nitrogen for hepatic TC content and molecular
analysis. 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGR), Lipoprotein receptors and apolipoproteins gene
expression in the liver were determined by real-time PCR.
Results: Intragastrical administration with berberine for 16 weeks lowered serum Hcy in rats fed with a high-fat
diet. In parallel, it also decreased body weight and improved serum TC and LDL-c. Berberine also tended to
decrease hepatic cholesterol. Consistently, berberine also upregulated LDL receptor (LDLR) mRNA level and
suppressed HMGR gene expression. Meanwhile, upon berberine-treated rats, there was a significant increase in
apolipoprotein E (apoE) mRNA, but no change in apoAI and scavenger receptor (SR) mRNA in the liver. Further, no
atherosclerotic lesions were developed in berberine-treated rats for 16 weeks.
Conclusion: Berberine can counteract HFD-elicited hyperhomocysteinemia and hyperlipidemia partially via
upregulating LDLR and apoE mRNA levels and suppressing HMGR gene expression.
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Homocysteine (Hcy) is a sulfur-containing amino acid
formed during the metabolism of methionine. Hyperho-
mocysteinemia (HHcy) as a potent pro-inflammatory
factor might accelerate the development of atheroscler-
osis [1]. Furthermore, the increased risk for vascular dis-
ease from elevated homocysteine is similar to that of
other major cardiovascular risk factors. More import-
antly, it is independent of these factors [2-4]. Thus, re-
ducing total Hcy levels can prevent the development of* Correspondence: gao.xin@zs-hospital.sh.cn
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reproduction in any medium, provided the orarterosclerotic vascular disease. But, now it remains un-
clear whether berberine affects the level of serum Hcy.
Berberine (BBR), a natural alkaloid extracted from Coptis
chinensis, is previously used for diarrhea treatment. In
1986, Chen et al. [5] at first reported that berberine can
lower serum glucose levels, besides anti-inflammatory.
Many studies [6-11] subsequently demonstrated that ber-
berine has also beneficial effects in the improvement of
lipid and glucose metabolism. Weight loss, lowering serum
low density lipoprotein cholesterol (LDL-c) and glucose
can prevent the development of arteriosclerosis. Thus,
these studies suggested that berberine have the potential
effect on preventing the development of atherosclerosis
for these beneficial metabolic effects.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Effects of berberine (BBR) on body weight and food
intake of rats. Male SD rats at 6 weeks of age received a high-fat
diet (HFD) or regular rodent chow. After 8 weeks of feeding, rats
were treated for 16 weeks with BBR or vehicle (n = 8 per group).
A: The body weight is the average weight of 8 rats at the beginning
of BBR treatment and after 16-week experiment. N, Normal control;
C, vehicle –treated rats fed with HFD; B, rats with berberine
treatment (200 mg/kg/d). B: Effects of BBR on food intake. The food
intake was measured every week. Values are mean± SEM. *p< 0.05vs
N; #p< 0.05 vs C.
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motes atherosclerosis development in apolipoprotein E-
deficient (apoE-/-) mice, which could counter-balance the
beneficial effect of lowering serum cholesterol [12].
ApoE-/- mouse is a well-established animal model for
studying atherosclerosis [13-15], but, the pathogenesis in
these mice is strikingly different from that of human ath-
erosclerosis. Thus, the potential of berberine for affecting
the level of serum homocysteine and atherosclerosis needs
to be more carefully investigated. This study will observe
the effects of berberine on atherogenic factors of athero-
sclerosis (e.g. serum Hcy and lipids) and the aortic lesion
in wild rats fed with a long-term high-fat diet.
Results
Berberine lowered serum hcy and improved typical risk
factors related to atherosclerosis in rats fed with a high-
fat diet (HFD)
The body weight of SD rats was gradually increased with
a high-fat diet for 24 weeks. Body weights of HFD-fed
rats were significantly reduced in BBR -treated group for
16 weeks (Figure 1A) as compared with control group
with no dramatic changes in food intake (Figure 1B).
Intragastrical administration with BBR for 16 weeks,
serum homocysteine was significantly decreased by
about 60% in contrast to the vehicle-treated rats fed with
the same high-fat diet (p< 0.001, Figure 2A). BBR treat-
ment significantly lowered the levels of serum TC (p<
0.05, Figure 2B) and LDL-c (p< 0.05, Figure 2C) as
compared with the placebo group in SD rats fed with a
high-fat diet. These data suggested that BBR exert antag-
onizing effects on HFD-induced dyslipidemia and hyper-
homocysteinemia in SD rats.
BBR decreased hepatic cholesterol in rats fed with HFD
The effects of berberine on total cholesterol level were
measured in rat liver. Rats fed with HFD alone showed a
significant (p< 0.001) increase in hepatic cholesterol con-
tent, when compared with the normal controls (Figure 3).
Treatment of high-fat diet-fed rats with berberine
(200 mg/kg/d) tended to reduce hepatic cholesterol level,
although this difference failed to reach statistical signifi-
cance when compared to the high-fat diet control.
Berberine reverses HFD-elicited abnormal expression of
some key genes related to cholesterol metabolism in the
liver
The effects of berberine on 3-hydroxy-3-methyl-glu-
taryl-CoA reductase (HMGR), lipoprotein receptors and
apolipoproteins gene expression in the liver of high-fat
diet-fed rats were investigated. The relative mRNA levels
of low-density lipoprotein receptor (LDLR) (p< 0.05,
Figure 4A) and apoE (p< 0.05, Figure 4B) was signifi-
cantly down-regulated in the livers of HFD-fed ratsrelative to the ND control group. BBR treatment signifi-
cantly reversed the downregulating effects of HFD on
the expression of LDLR and apoE (p< 0.05). On the
other hand, the level of HMGR mRNA was increased in
rats fed with long-term high-fat diet, which was mark-
edly lowered by BBR treatment (p< 0.05, Figure 4A).
We also found that apoB and apoAI mRNAs were sup-
pressed by HFD feeding (p< 0.05, Figure 4B), but these
were not affected by BBR treatment. Despite these
changes, BBR and high-fat-diet feeding did not influence
the expression of scavenger receptor (SR).
Effect of BBR treatment for 16 weeks on aortic lesions in
rats fed with a high-fat diet
Histological analysis by HE staining of the aorta showed
that the tunica intima of aorta remained smooth and in-
tact in rats with a 24- weeks high-fat diet after treatment
with berberine for 16 weeks (Figure 5A-D). The results
Figure 2 Effects of berberine (BBR) on serum Hcy and lipid
profile. Serum Hcy (A), TC (B) and LDL-c (C) are the average of each
group (n = 8). N, Normal control; C, vehicle –treated rats fed with
HFD; B, rats with berberine treatment (200 mg/kg/d). Values are
mean± SEM. *p< 0.05vs N; #p< 0.05 vs C.
Figure 3 Effects of berberine (BBR) on hepatic total cholesterol. N,
Normal control; C, vehicle –treated rats fed with HFD; B, rats with
berberine treatment (200 mg/kg/d). Values are mean±SEM. Significance
was assessed by one-way ANOVA followed by Tukey's Multiple
Comparison test. Data are mean±SEM. *p< 0.05, **p< 0.01 vs N.
Figure 4 The effects of berberine on 3-hydroxy-3-methyl-
glutaryl-CoA reductase (HMGR), Lipoprotein receptors and
apolipoproteins gene expression. Real-time quantitative PCR
analysis of LDLR, HMGR and SR (A) and apolipoproteins (B) in the
livers of SD rats administrated with berberine or vehicle (n = 8 per
group). Relative mRNA amounts of each gene were normalized to
that of beta-actin. Values are mean± SEM. *p< 0.05vs N;
#p< 0.05 vs C.
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inclusions and foam cell accumulation were seen in the
aortic endothelium of these rats (Figure 5E-H). Further-
more, in other rats fed with a high-fat diet without ad-
ministration of berberine, there were also no deposits of
monocyte-derived macrophages and abnormal fatty
Figure 5 (See legend on next page.)
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Figure 5 Effects of berberine (BBR) on the aorta of rats fed with a high-fat diet. After BBR treatment for 16 weeks, rats were killed after a
14-hour fast. Histological analysis of the aorta of the HFD-fed rats treated with vehicle (C group) or BBR (B group). The aorta sections were stained
with hematoxylin and eosin (A-D) or with Sudan Ш (E-I) to evaluate the pathologic structures. Representative photographs are shown. A-B, E-F:
Photographs are at × 50 magnification, C-D, G-H: Photographs are at × 400 magnification.
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that no atherosclerotic lesions were developed in
berberine-treated for 16 weeks and control rats fed with
a long-term high-fat diet.
Discussion
In this study, we have shown that berberine could de-
crease serum homocysteine level and many known risk
factors related to atherosclerosis, such as body weight,
serum cholesterol, and LDL-c in SD rats fed with a
high-fat diet. Consistently berberine could upregulate
LDLR and apoE, and downregulate HMGR gene expres-
sion in the liver. Importantly, our morphological results
demonstrated that berberine do not increase the devel-
opment of atherosclerosis in SD rats fed with a long-
term high-fat diet.
Recent studies demonstrate that hyperhomocysteine-
mia (HHcy) as a potent pro-inflammatory factor
increases the risk for the development of atherosclerosis,
which is independent of these typical cardiovascular risk
factors [1-4]. The results of a meta-analysis [16] includ-
ing 27 studies relating homocysteine to arteriosclerotic
vascular disease and 11 studies of folic acid effects on
serum homocysteine levels population-based case–con-
trol studies showed that a 5-mu mol/L total Hcy (tHcy)
increment causes a 1.6-fold and a 1.8-fold increase in
risk for coronary artery disease (CAD) for men and
women, respectively. Further, a total of 10% of the popu-
lation's CAD risk appears attributable to tHcy. The OR
for cerebrovascular disease (5-mu mol/L tHcy incre-
ment) is 1.5 (95% CI, 1.3 to 1.9) and Peripheral arterial
disease also showed a strong association. The present
study showed that rats fed with HFD alone (n = 8)
showed a significant increase in serum Hcy at the end of
16 weeks’ treatment, when compared with the normal
controls fed a standard diet alone. High-fat diet-fed rats
treated with berberine exhibited a significant reduction
in serum Hcy by 1.3-fold compared with the high-fat
diet treated rats alone. BBR can decrease homocysteine,
which indicated that berberine have a beneficial effect in
preventing atherosclerosis.
Dyslipidemia is the most important modifiable risk
factor of atherosclerosis. The present study demon-
strated that administration of berberine along with the
high-fat diet effectively reduced serum TC and LDL-c in
concordance with other reports [6-11]. Plasma choles-
terol level is determined by the net balance between theinput of cholesterol into plasma (biosynthesis) and re-
moval rate from plasma [17,18]. The former is mainly
dependent on the availability of the rate-limiting en-
zyme, HMG-CoA reductase (HMGR). High level of hep-
atic LDLR mRNA is associated with improved clearance
of plasma LDL-c [17]. Apolipoproteins are carrier pro-
teins that bind lipids to form lipoprotein particles and
also serve as enzyme cofactors and lipid transfer carriers
that regulate the metabolism of lipoprotein. Thus, the
removal rate from plasma in part is related to the level
of LDLR and apolipoproteins. We measured mRNA of
lipoprotein receptors, apolipoproteins and HMGR in the
liver of rats after chronic treatment with berberine. We
observed that administration of berbeine significantly
upregulated LDLR and apoE gene expression in the liver
of rats fed with a high-fat diet. On the contrary, elevated
gene expression of hepatic HMGR in long-term HFD-
fed rats was down-regulated upon treatment of berber-
ine. Apolipoprotein E (apoE) is synthesized by the liver
that mediates the transport and uptake of cholesterol
and lipid by way of its high affinity interaction with dif-
ferent cellular receptors, including the low-density lipo-
protein (LDL) receptor[19]. One study showed that apoE
deficiency causes high serum cholesterol and triglyceride
levels and leads to premature artherosclerosis [20]. The
previous study indicated that BBR reduces serum choles-
terol, LDL-cholesterol via elevating hepatic LDLR gene
expression through a post-transcriptional mechanism
that stabilizes its mRNA [7]. Thus, BBR might increase
more clearance of serum LDL-c through its action on
LDLR and apoE and reduce cholesterol biosynthesis by
suppressing HMGR gene expression.
ApoB is the primary apolipoproteins of chylomicrons
and low-density lipoproteins. While it is unclear exactly
what functional role apoB plays in LDL, it is the primary
apolipoprotein component and is absolutely required for
its formation. Lipids are normally exported from the
liver in very-low-density lipoproteins (VLDLs), which
are complex lipoprotein particles that involve the fusion
of a newly synthesized apolipoprotein B-100 (apoB-100)
molecule with a triglyceride droplet through the action
of microsomal triglyceride transfer protein (MTTP) [21].
A reduction in MTTP function and apoB synthesis and
secretion may impair hepatic lipid export and favour tri-
glyceride accumulation in the liver [22,23]. In our previ-
ous study [11], long-term high-fat-diet induced
significant fat accumulation in rat liver via inhibiting the
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MTTP function. In this study, apoB gene expression was
down-regulated in the liver of rats fed with long-term
high-fat-diet compared with normal control rats, but
berberine did not affect it. Thus, these suggested that
long-term high-fat diet could simultaneously reduce
apoB synthesis to favor fat accumulation in the liver,
which needs further investigation.
Meanwhile, apoAI mRNA level was decreased in the
liver of rats fed with long-term high-fat-diet compared
with normal control rats, but berberine also did not
affect it.
Atherosclerosis is a systemic inflammatory disease
which is associated with several genetic and environ-
mental risk factors. Epidemiologic, clinical and experi-
mental studies show that Long-term intake of high-
calories food leads to metabolic derangements character-
ized by hyperlipidemia and hyperglycemia, which
induced the development of atherosclerosis. Thus, SD
rats fed with a high-fat diet is a well-established animal
model of reproducing the risk factors of premature ath-
erosclerosis development in human [24-27].
Atherosclerosis/angiostasis partially stems from the in-
jury or phenotypic alteration of endothelial cells (ECs),
the cells in the frontline against vascular disturbances
[28]. The histological examination of HHcy rats revealed
an increased recruitment of monocytes to aortic endo-
thelium accompanied by elevated immunostaining for
monocyte chemoattractant protein-1, vascular cell adhe-
sion molecule-1 and E-selectin [29]. The present study
showed that no abnormal fatty deposits in the intima of
arteries were observed and the intima of aorta remained
intact in rats fed with a long-term high-fat diet after ad-
ministration of berberine by gavage for 16 weeks. So
berberine could prevent the aortic lesion, which may
partially be through above-mentioned mechanism.
Although morphological results also showed no ath-
erosclerotic lesions developed in control group, berber-
ine can improve serum homocysteine and several typical
risk factors associated with atherosclerosis, and there is
not atherosclerotic lesions observed in berberine-treated
group. These results at least suggest that berberine does
not promote atherosclerosis development in SD rats fed
with long-term high-fat diet.
In contrast to the present results, a recent study showed
that berberine can induce foam cell formation and pro-
motes atherosclerosis development in apolipoprotein E-
deficient (apoE-/-) mice, which could counter-balance the
beneficial effect of lowering serum cholesterol [12]. And
the apoE-/- mice are gene-deficient animal model, in
which targeted deletion of apoE gene leads to severe
hypercholesterolemia and spontaneous. The apoE-/-
model has been used widely due to the rapid development
of atherosclerosis, despite considerable limitations. Amajor fault is that plasma cholesterol level is about
8 mmol/L on chow diet, compared with 2 mmol/L for the
parent C57Bl/6 mouse, and can increase >70 mmol/L on
a high-fat, high-cholesterol (HFC) diet [30]. Another main
shortcoming is that most plasma cholesterol is confined
to VLDL and not to LDL articles as in humans. Therefore,
the different results of these studies are mainly due to the
animal model. Our present study at least demonstrated
that berberine did not increase the risk of atherosclerosis
in SD rats fed with a long-term high-fat diet, although
these rats are not the typical model of atherosclerosis.
In summary, the present study has demonstrated that
berberine can decrease serum homocysteine and several
traditional risk factors associated with atherosclerosis via
regulating LDLR, apoE and HMGR gene expression in
rats fed with high-fat diet. Our findings illustrate that
berberine may represents a promising agent for the pris-
tine prevention of atherosclerosis.
Methods
Berberine, serum triglyceride determination Kit, and
LDL-c Kit were purchased from Sigma-Aldrich, St.
Louis, MO.
Animal experiment
The animal component of this study has been described
in detail in our recently published data [11]. Briefly,
healthy male Sprague –Dawley (SD) rats [Grade SPF, cer-
tificate number of the breeder: SCXK(Hu) 2007-0005]
weighing 190-210 g from the Animal Development Center
(Chinese Academy of Sciences, Shanghai, China) were
given free access to food and water and were maintained
on a 12/12-hour light/dark cycle. Rats received either a
regular rodent chow (normal diet: 62.3% carbohydrate/
12.5% fat/24.3% protein calories) or a high-fat diet (32.6%
carbohydrate/51.0% fat/16.4% protein calories) for
24 weeks. After 8 weeks of feeding, rats on the HFD
received randomly intragastric injection of either berber-
ine (200 mg  kg-1 day-1) or vehicle for 16 weeks. Rats fed
the normal diet received the equal volume of vehicle
(0.5% methylcellulose, N group) as a control group. After
an overnight fasting period, blood samples were also col-
lected for measurement of serum Hcy, TC and LDL-c
levels using commercially available kits. The liver tissues
were stored in liquid nitrogen for biochemical and mo-
lecular analysis.
All experimental procedures involving the use of ani-
mals were conducted in conformity with PHS policy and
were approved by the Animal Use and Care Committee
of Fudan University.
Measurement of serum hcy by ELISA
Serum homocysteine ELISA kit was from Maibiotech-
nology, China. Add 100μl each of dilutions of standard,
Table 1 Primer sequences for real-time quantitative PCR
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and incubate for 2 hours at 37°C. Remove the liquid of
each well, and wash with 400 of 1X Wash Solution to
each well. Then add 100μl of biotinylated antibody
working solution to each well. After incubate for 1 hour,
washing the wells. Add 100μl of enzyme conjugate work-
ing solution to each well. Incubate for 30 minutes at
37°C after covering it with the Plate sealer. Aspirate the
solution and wash with 400μl of 1X Wash Solution to
each well. Then add 100μl of TMB solution working so-
lution to each well. Incubate for 15 minutes at 37°C after
covering it with the Plate sealer. Protect from light. Add
50μl of Stop Solution to each well. Then, run the micro-
plate reader and conduct measurement at 450 nm
immediately.
Measurement of serum TC
Amplex red cholesterol assay kit (A12216) was
obtained from invitrogen detection technologies. Pre-
pare a cholesterol standard curve. Dilute serum in
1XReaction Buffer. Pipet 50μl of the diluted samples
and controls into separate wells of a microplate.
Begin the reactions by adding 50μl of the Amplex
Red reagent/HRP/cholesterol oxidase/cholesterol es-
terase working solution to each microplate well con-
taining the samples and controls. Incubate the
reactions for 30minutes at 37°C, protected from light.
Measure the fluorescence in a fluorescence micro-
plate reader using excitation in the range of 530-
560 nm and emission detection at ~ 590 nm. Accord-
ing to the standard curve, get the cholesterol level of
each sample.
Measurement of serum LDL-c
Prepare working solution containing cholesterol oxidase/
cholesterol esterase/catalase/peroxidase. Pipet 5μl of the
diluted samples and controls into separate wells of a
microplate. Then add 500μl of working solution to each
microplate well. Mix well and incubate the reactions in
the 37°C water bath for 10 minutes. Measure the absorb-
ance value at 546 nm.
Hepatic total cholesterol level
Hepatic lipids were extracted according to the method
of Folch et al. [31]. Briefly, lipid was extracted from fro-
zen liver tissues (30 mg) by homogenization in 1 ml of
2:1 chloroform: methanol, followed by shaking at room
temperature for overnight and centrifugation at
3000 rpm for 10 min. Aliquots (400 l) of the organic-
extract lipid suspension were analyzed for hepatic total
cholesterol concentration using commercial diagnostic
kits. Hepatic TC content was defined as mg of choles-
terol per gram of the liver.Histological analysis
After the rats (n = 8 pre group) were sacrificed, the aor-
tas were removed from the region of the proximal aorta
and fixed in phosphate-buffered 10% formalin, which
was subsequently stained with hematoxylin and eosin
(HE). The aorta was then divided into 2 sections, one of
which was embedded in paraffin blocks and the other in
O.C.T. compound. A section from each paraffin block
was stained with HE to examine the pathologic struc-
tures of the aorta and serial cryosections (five consecu-
tive slices each sample) were stained with Sudan Ш to
evaluate aortic lesion. These pathological slices were
observed by the experienced pathologists in blinded
state.
Real-time quantitative PCR (qPCR) analysis
Total RNA was isolated from liver tissues using Trizol
reagent (Invitrogen, Carlsbad, CA, USA). cDNA was
synthesized by reverse transcription using ReverTra Ace
(Toyobo, Osaka, Japan). The SYBR Green PCR Master
Mix (Toyobo, Osaka, Japan) was used for qPCR with a
sequence detection system (ABI PRISM7900, Applied
Biosystems, Foster City, CA, USA). EightμL reaction
mixture contained 1μL of cDNA and 125 nmol/L of
primers. The specific primers of PCR amplification are
described in Table 1. The same reaction was performed
in triplicate with The relative gene expression was calcu-
lated using the 2−ΔΔCt as described previously [32].
Statistical analysis
All data were presented as mean ± SEM. Significance
was assessed by Sudent’s t-test. All p values were two-
tailed and p values of less than 0.05 were considered to
be statistically significant.
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